Surgical Treatment of Hip Fractures Under Peripheral Regional Anesthesia

Helios Research Center

Status: Completed

Conditions: Hip Fractures

Treatments: Drug: Ropivacaine (lumbar plexus block L2-L4); Drug: Ropivacaine (sciatic nerve block); Drug: Ropivacaine (lumbar plexus block Th12-L1)

Study type: Interventional

Funder types: Other

Identifiers

NCT04005404

A 2018 0237

Details and patient eligibility

About

The study investigates whether treatment of proximal femoral fractures is possible using a peripheral regional anesthesia technique.

Full description

The study investigates whether treatment of proximal femoral fractures is possible using a peripheral regional anesthesia technique.

After positioning on the non-fractured side, a double injection technique is used (dual guidance concept: nerve stimulation and sonography).

The injections are performed parasacrally (blockade of the sacral plexus under the piriformis muscle) and lumbar paravertebrally (psoas compartment block and transmuscular quadratus lumborum block). Per block 20 ml ropivacaine 0.375% is administered (total dose: 225mg ropivacaine).

The study examines the success rate (rate of successfully performed nerve blockade; need for supplemental medication: sufentanil and/or propofol; conversion rate to general anesthesia), circulatory stability (need for application of ephedrine or norepinephrine) and side effects.

Enrollment: 80 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• proximal femoral fracture
• older then 18 years
• written informed consent

Exclusion criteria

• local or systematic inflammation
• allergy to ropivacaine
• participate in other studies
• body mass index over 35
• periprosthetic fractures

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

80 participants in 3 patient groups

intertrochanteric femoral fractures

Experimental group

Description:

geriatric patients with intertrochanteric femoral fracture who have consented to the study intervention

Treatment:

Drug: Ropivacaine (lumbar plexus block Th12-L1)

Drug: Ropivacaine (lumbar plexus block L2-L4)

Drug: Ropivacaine (sciatic nerve block)

neck femur fractures

Experimental group

Description:

geriatric patients with neck of femur fracture who have consented to the study intervention

Treatment:

Drug: Ropivacaine (lumbar plexus block Th12-L1)

Drug: Ropivacaine (lumbar plexus block L2-L4)

Drug: Ropivacaine (sciatic nerve block)

subtrochanteric femoral fractures

Experimental group

Description:

geriatric patients with subtrochanteric femoral fracture who have consented to the study intervention

Treatment:

Drug: Ropivacaine (lumbar plexus block Th12-L1)

Drug: Ropivacaine (lumbar plexus block L2-L4)

Drug: Ropivacaine (sciatic nerve block)